
|Articles|July 1, 2003
VISX gets OK from FDA; investors block takeover
Santa Clara, CA-VISX Inc. is celebrating the FDA approval of its CustomVue laser-vision correction procedure, as its board survived an attempt to dethrone one member in a takeover plan by financier Carl C. Icahn.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Lotus submits NDA in South Korea for LENZ’s presbyopia treatment VIZZ
2
Belite Bio releases topline results from phase 3 DRAGON trial of Tinlarebant for STGD1
3
Collarettes common but largely stable in moderate-to-severe dry eye patients
4
EYDENZELT, Celltrion’s biosimilar referencing EYLEA, approved in Canada
5

















































.png)


